# DUSP6

## Overview
DUSP6, or dual specificity phosphatase 6, is a gene that encodes a protein belonging to the dual-specificity phosphatase family, which is involved in the dephosphorylation of both tyrosine and serine/threonine residues. The protein encoded by DUSP6 plays a pivotal role in the regulation of the mitogen-activated protein kinase (MAPK) signaling pathway, specifically targeting extracellular signal-regulated kinases 1 and 2 (ERK1/2) (Beaudry2018Dual‐specificity; Bermudez2010The). As a cytoplasmic phosphatase, DUSP6 modulates cellular processes such as proliferation, differentiation, and apoptosis by inactivating ERK1/2, thereby acting as a critical regulator of cellular signaling dynamics (Bermudez2010The). The protein's activity and stability are influenced by post-translational modifications, including SUMOylation, which enhances its function and protects it from degradation (Ma2020DUSP6). DUSP6 has been implicated in various physiological and pathological contexts, including cancer, where its expression levels can influence tumorigenic processes (Ruckert2024The; Furukawa2003Potential).

## Structure
DUSP6, also known as dual specificity phosphatase 6, is a protein involved in the dephosphorylation of both tyrosine and serine/threonine residues. It is part of the VH1-like/dual-specificity phosphatases group, which is a subset of class I Cys-based phosphatases (Ruckert2024The). The protein contains a dual specificity phosphatase domain, which is typical of the protein tyrosine phosphatase family, and a rhodanese domain (Jeong2014The).

The structure of DUSP6 includes a catalytic domain that is crucial for its function in the MAPK signaling pathway. This domain is characterized by a loop-to-strand switch near the active site, which is essential for forming a binary complex with extracellular receptor kinase (ERK). This structural transition significantly increases the phosphatase activity of DUSP6 (Jeong2014The). The active site of DUSP6 contains a conserved loop with an HCX5R motif, which is a common feature among dual-specificity phosphatases (Jeong2014The).

DUSP6 is subject to post-translational modifications such as phosphorylation, which can affect its activity and stability (Pulido2019Dual). The protein's structure and function are influenced by the presence of ions like chloride and phosphate in the active-site pockets, contributing to the stability of its conformation (Jeong2014The).

## Function
DUSP6, or dual specificity phosphatase 6, plays a critical role in regulating cellular processes by modulating the MAPK/ERK signaling pathway. It specifically dephosphorylates and inactivates ERK1/2 MAPK, which is essential for controlling cellular proliferation, differentiation, and apoptosis (Beaudry2018Dual‐specificity; Bermudez2010The). DUSP6 is primarily active in the cytoplasm, where it acts as a cytoplasmic anchor for inactive ERK, facilitating the transport of dephosphorylated ERKs from the nucleus to the cytosol (Bermudez2010The).

In healthy human cells, DUSP6 is involved in maintaining mitochondrial dynamics and protecting cells from oxidative damage. It achieves this by dephosphorylating Drp1 at serine 616, which is crucial for preventing mitochondrial fragmentation and apoptosis under oxidative stress conditions (Ma2020DUSP6). The stability and function of DUSP6 are enhanced by SUMOylation, which protects it from degradation and ensures its cytoprotective role (Ma2020DUSP6).

DUSP6 also plays a role in regulating the Ras-MAPK signaling cascade, particularly through its interaction with ERK1/2, and is involved in various developmental processes and cellular responses (Bermudez2010The). Its activity is modulated by SUMOylation, which enhances its phosphatase activity and stability (Ma2020DUSP6).

## Clinical Significance
Mutations and alterations in the expression of the DUSP6 gene have been implicated in various diseases, particularly cancers. In pancreatic cancer, DUSP6 acts as a tumor suppressor. Its expression is often lost in invasive carcinoma cells, which may contribute to the progression of the disease by allowing unchecked ERK activation due to KRAS mutations (Kidger2022Suppression; Furukawa2003Potential). In contrast, DUSP6 overexpression in glioblastoma is associated with increased tumorigenicity, suggesting an oncogenic role in this context (Ruckert2024The).

In acute myeloid leukemia (AML), high DUSP6 expression is linked to resistance to JAK2 inhibitors and disease progression. Inhibition of DUSP6 in these cells can lead to cell cycle arrest and apoptosis, highlighting its potential as a therapeutic target (Kong2021DUSP6). In colorectal cancer, reduced DUSP6 expression is associated with advanced tumor stages and increased aggressiveness, indicating its role in tumor suppression (Beaudry2018Dual‐specificity).

DUSP6 is also overexpressed in papillary and poorly differentiated thyroid carcinomas, where it may contribute to the neoplastic properties of these cancer cells (Degl’Innocenti2012DUSP6MKP3). Additionally, a missense mutation in DUSP6 has been associated with Class III malocclusion, suggesting its involvement in developmental abnormalities (Nikopensius2013A).

## Interactions
DUSP6, also known as MKP-3, is a dual-specificity phosphatase that specifically interacts with ERK1/2, a subset of MAP kinases. This interaction is facilitated by the Kinase Interaction Motif (KIM) within DUSP6, which allows it to bind to the common docking (CD) domain of ERK2. This binding is crucial for the catalytic activation of DUSP6, enabling it to dephosphorylate ERK1/2 effectively (Zhou2006Mapping; Arkell2008DUSP6MKP3). 

DUSP6 does not interact with ERK5, as demonstrated by experiments showing the inability of DUSP6 to bind or inactivate ERK5, despite its structural similarity to ERK1/2 (Arkell2008DUSP6MKP3). The specificity of DUSP6 for ERK1/2 is further supported by the identification of specific amino acids in ERK2 that are essential for binding, such as Tyr 215, Leu 246, and Tyr 255, which are involved in high-affinity interactions (Zhou2006Mapping).

The interaction between DUSP6 and ERK2 is not only structural but also functional, as it enhances the phosphatase activity of DUSP6, leading to the dephosphorylation of ERK2 and subsequent regulation of cellular processes like proliferation and differentiation (Jeong2014The; Maillet2008DUSP6).


## References


1. (Kong2021DUSP6) DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. This article has 2 citations.

[2. (Zhou2006Mapping) Bo Zhou, Jialin Zhang, Sijiu Liu, Sharanya Reddy, Fang Wang, and Zhong-Yin Zhang. Mapping erk2-mkp3 binding interfaces by hydrogen/deuterium exchange mass spectrometry. Journal of Biological Chemistry, 281(50):38834–38844, December 2006. URL: http://dx.doi.org/10.1074/jbc.m608916200, doi:10.1074/jbc.m608916200. This article has 46 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m608916200)

[3. (Kidger2022Suppression) Andrew M. Kidger, Mark K. Saville, Linda K. Rushworth, Jane Davidson, Julia Stellzig, Motoharu Ono, Ludwig A. Kuebelsbeck, Klaus-Peter Janssen, Bernhard Holzmann, Jennifer P. Morton, Owen J. Sansom, Christopher J. Caunt, and Stephen M. Keyse. Suppression of mutant kirsten-ras (krasg12d)-driven pancreatic carcinogenesis by dual-specificity map kinase phosphatases 5 and 6. Oncogene, 41(20):2811–2823, April 2022. URL: http://dx.doi.org/10.1038/s41388-022-02302-0, doi:10.1038/s41388-022-02302-0. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-022-02302-0)

[4. (Furukawa2003Potential) Toru Furukawa, Makoto Sunamura, Fuyuhiko Motoi, Seiki Matsuno, and Akira Horii. Potential tumor suppressive pathway involving dusp6/mkp-3 in pancreatic cancer. The American Journal of Pathology, 162(6):1807–1815, June 2003. URL: http://dx.doi.org/10.1016/s0002-9440(10)64315-5, doi:10.1016/s0002-9440(10)64315-5. This article has 173 citations.](https://doi.org/10.1016/s0002-9440(10)64315-5)

[5. (Beaudry2018Dual‐specificity) Katia Beaudry, Marie‐Josée Langlois, Amélie Montagne, Sébastien Cagnol, Julie C. Carrier, and Nathalie Rivard. Dual‐specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis. Journal of Cellular Physiology, 234(5):6731–6745, October 2018. URL: http://dx.doi.org/10.1002/jcp.27420, doi:10.1002/jcp.27420. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.27420)

[6. (Bermudez2010The) O. Bermudez, G. Pagès, and C. Gimond. The dual-specificity map kinase phosphatases: critical roles in development and cancer. American Journal of Physiology-Cell Physiology, 299(2):C189–C202, August 2010. URL: http://dx.doi.org/10.1152/ajpcell.00347.2009, doi:10.1152/ajpcell.00347.2009. This article has 173 citations.](https://doi.org/10.1152/ajpcell.00347.2009)

[7. (Degl’Innocenti2012DUSP6MKP3) Debora Degl’Innocenti, Paola Romeo, Eva Tarantino, Marialuisa Sensi, Giuliana Cassinelli, Veronica Catalano, Cinzia Lanzi, Federica Perrone, Silvana Pilotti, Ettore Seregni, Marco A Pierotti, Angela Greco, and Maria Grazia Borrello. Dusp6/mkp3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. Endocrine-Related Cancer, 20(1):23–37, November 2012. URL: http://dx.doi.org/10.1530/erc-12-0078, doi:10.1530/erc-12-0078. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1530/erc-12-0078)

[8. (Ma2020DUSP6) Ruining Ma, Lina Ma, Weiji Weng, Yingping Wang, Huiqing Liu, Rongjun Guo, Yingwei Gao, Jun Tu, Tian-Le Xu, Jinke Cheng, Michael X. Zhu, Aiwu Zhou, and Yong Li. Dusp6 sumoylation protects cells from oxidative damage via direct regulation of drp1 dephosphorylation. Science Advances, March 2020. URL: http://dx.doi.org/10.1126/sciadv.aaz0361, doi:10.1126/sciadv.aaz0361. This article has 50 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/sciadv.aaz0361)

[9. (Nikopensius2013A) T. Nikopensius, M. Saag, T. Jagomägi, T. Annilo, M. Kals, P.A. Kivistik, L. Milani, and A. Metspalu. A missense mutation in dusp6 is associated with class iii malocclusion. Journal of Dental Research, 92(10):893–898, August 2013. URL: http://dx.doi.org/10.1177/0022034513502790, doi:10.1177/0022034513502790. This article has 46 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1177/0022034513502790)

10. (Ruckert2024The) The role of dual-specificity phosphatase 6 (DUSP6) in metastasis and metabolism of pancreatic cancer cells. This article has 0 citations.

[11. (Arkell2008DUSP6MKP3) Rebecca S. Arkell, Robin J. Dickinson, Matthew Squires, Shaista Hayat, Stephen M. Keyse, and Simon J. Cook. Dusp6/mkp-3 inactivates erk1/2 but fails to bind and inactivate erk5. Cellular Signalling, 20(5):836–843, May 2008. URL: http://dx.doi.org/10.1016/j.cellsig.2007.12.014, doi:10.1016/j.cellsig.2007.12.014. This article has 66 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2007.12.014)

[12. (Pulido2019Dual) Rafael Pulido and Roland Lang. Dual specificity phosphatases: from molecular mechanisms to biological function. International Journal of Molecular Sciences, 20(18):4372, September 2019. URL: http://dx.doi.org/10.3390/ijms20184372, doi:10.3390/ijms20184372. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms20184372)

[13. (Jeong2014The) Dae Gwin Jeong, Chun Hua Wei, Bonsu Ku, Tae Jin Jeon, Pham Ngoc Chien, Jae Kwan Kim, So Ya Park, Hyun Sook Hwang, Sun Young Ryu, Hwangseo Park, Deok-Soo Kim, Seung Jun Kim, and Seong Eon Ryu. The family-wide structure and function of human dual-specificity protein phosphatases. Acta Crystallographica Section D Biological Crystallography, 70(2):421–435, January 2014. URL: http://dx.doi.org/10.1107/s1399004713029866, doi:10.1107/s1399004713029866. This article has 36 citations.](https://doi.org/10.1107/s1399004713029866)

[14. (Maillet2008DUSP6) Marjorie Maillet, Nicole H. Purcell, Michelle A. Sargent, Allen J. York, Orlando F. Bueno, and Jeffery D. Molkentin. Dusp6 (mkp3) null mice show enhanced erk1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. Journal of Biological Chemistry, 283(45):31246–31255, November 2008. URL: http://dx.doi.org/10.1074/jbc.m806085200, doi:10.1074/jbc.m806085200. This article has 143 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m806085200)